Autonomous Healthcare Receives FDA De Novo Marketing Authorization for Syncron-E™, the First Device in a New FDA Category of Ventilator Waveform Analysis Software
RegulatoryapprovedSyncron-E™Positive
AI Analysis
Summary
Autonomous Healthcare announced FDA De Novo Marketing Authorization for Syncron-E™, ventilator waveform analysis software designed to help respiratory therapists identify ineffective patient-ventilator asynchrony. This approval establishes a new FDA device category for this type of software.
Outcome Details
FDA De Novo Marketing Authorization granted for Syncron-E™, establishing a new FDA device category for ventilator waveform analysis software
Importance:8/10
Sentiment:
0.95
FDA approvalDe Novomedical devicesoftwarerespiratoryventilator
Read the original article
Published by PR Newswire Pharma on July 14, 2026 12:38 PM